Introduction to Assembly Biosciences Inc.

Assembly Biosciences Inc. is a clinical-stage biotechnology company dedicated to revolutionizing the treatment of serious viral diseases, with a primary focus on hepatitis B virus (HBV). Headquartered in New York, New York, the company leverages cutting-edge science and proprietary small-molecule platforms to develop oral therapies that target the viral life cycle at multiple stages. With a market reputation as a top innovator in the healthcare and biopharmaceutical industry, Assembly Biosciences Inc. is recognized for its deep expertise in virology, its robust pipeline of core inhibitors, and its commitment to improving outcomes for millions of patients worldwide.

The company’s profile reflects a rare combination of academic rigor and commercial agility, earning partnerships with leading research institutions and a strong presence in the global HBV treatment landscape. Assembly Biosciences Inc. has positioned itself at the forefront of antiviral research, addressing unmet medical needs in chronic hepatitis B infection—a disease affecting over 250 million people globally. Organizations ranging from pharmaceutical giants to public health agencies rely on Assembly Biosciences Inc. for innovative therapeutic candidates and collaborative research frameworks.

As a Healthcare industry leader, Assembly Biosciences Inc. has built a reputation for scientific excellence, ethical clinical practices, and transparent stakeholder communication. The company’s stock is publicly traded on NASDAQ under the ticker ASMB, reflecting investor confidence in its pipeline and strategic vision. With a dedicated workforce of over 150 employees—including PhDs, MDs, and seasoned executives—Assembly Biosciences Inc. continues to expand its footprint in antiviral drug development, offering a dynamic environment for top talent in the life sciences.

Company History and Business Evolution

Assembly Biosciences Inc. was founded in 2014 by a team of veteran virologists and entrepreneurs who recognized an urgent need for better HBV therapeutics. The company began as a spin-out from a prominent academic research center, leveraging groundbreaking discoveries in HBV core protein structure and function. Early development focused on assembling a library of core inhibitors that could disrupt the capsid assembly process—a novel mechanism distinct from traditional nucleoside analogs.

Within three years, Assembly Biosciences Inc. advanced its lead candidate, ABI-H0731, into Phase 1 clinical trials, achieving proof-of-concept data that demonstrated potent antiviral activity. This milestone attracted strategic partnerships with larger biopharma firms and enabled the company to raise significant venture capital. In 2018, Assembly Biosciences Inc. went public via an initial public offering (IPO), raising $75 million to fuel its pipeline expansion.

The company’s evolution accelerated with the acquisition of additional preclinical assets targeting the HBV surface antigen (HBsAg) secretion and entry inhibitors. By 2021, Assembly Biosciences Inc. had initiated multiple Phase 2 studies, including combination trials with standard-of-care agents. Despite setbacks in some clinical endpoints, the company pivoted to optimize its drug candidates using next-generation core inhibitors and prodrug strategies. Today, Assembly Biosciences Inc. is entering a new phase of growth, with several programs in mid-stage development and a renewed focus on curative combination regimens. The company’s history reflects resilience, strategic adaptability, and a relentless pursuit of scientific breakthroughs—traits that have solidified its position as a top Healthcare innovator.

Assembly Biosciences Inc. at a Glance

• Headquarters: New York, New York, USA
• Founded: 2014
• CEO: William S. Doyle (as of 2025)
• Revenue: Approximately $25 million (2024, primarily from partnerships and grants)
• Employees: 150–200 professionals
• Stock Symbol: NASDAQ: ASMB
• Industry: Biotechnology / Pharmaceuticals – Virology
• Core Focus: Oral therapies for chronic hepatitis B virus (HBV)
• Pipeline: ABI-H0731, ABI-H2158, and next-generation core inhibitors
• Clinical Stage: Phase 2 for lead candidate
• Partnerships: Collaborations with academic institutions and global health organizations
• Research Sites: New York, NY; South San Francisco, CA
• Patents: Over 30 issued patents covering capsid inhibitor compositions
• Funding Raised: Over $200 million from VC and public markets
• Key Competitors: Gilead Sciences, Arbutus Biopharma, Janssen Pharmaceuticals
• Regulatory Status: Fast Track designation from FDA for lead program
• Mission: To cure hepatitis B through innovative oral therapies
• Community Outreach: Active partnerships with HBV patient advocacy groups
• Workplace Rating: 4.2/5 on Glassdoor
• Recent Innovation: Prodrug platform for improved oral bioavailability

Mission, Vision, and Core Corporate Values

Assembly Biosciences Inc.’s mission is to develop transformative oral therapies that cure chronic hepatitis B virus infection, freeing patients from lifelong treatment. The vision extends to becoming the global leader in HBV antiviral research, setting the standard for combination regimens that achieve functional cure. Core values include scientific integrity, patient centricity, collaboration, transparency, and relentless innovation. Every decision at Assembly Biosciences Inc. is guided by a deep commitment to ethical research, robust data sharing, and inclusive communication across all stakeholders. The company believes that breakthrough science must be accessible, and thus maintains open dialogues with regulatory bodies and patient communities.

Business Strategy and Future Roadmap

Assembly Biosciences Inc. employs a four-pronged business strategy: first, advancing its core inhibitor pipeline through Phase 3 readiness; second, expanding into combination therapies that target multiple viral life cycle stages; third, forging strategic alliances with larger biopharma companies for late-stage development and commercialization; and fourth, leveraging its prodrug platform to enhance oral bioavailability and patient compliance. The future roadmap includes initiating a pivotal Phase 3 trial for its lead candidate by 2026, exploring HBV functional cure endpoints, and expanding into other viral diseases such as hepatitis D and herpesviruses. The company also plans to double its research workforce over the next three years and invest in gene expression analysis tools to uncover resistance mechanisms.

Products, Technologies, and Services

Core Inhibitor Platform: Assembly Biosciences Inc. specializes in oral small-molecule CpAMs (core protein allosteric modulators) that inhibit HBV capsid assembly, thereby blocking viral replication and reducing cccDNA formation. Lead candidates include ABI-H0731 (Phase 2) and ABI-H2158 (Phase 1). Prodrug Technology: A proprietary lipid-conjugation system that improves solubility and gastrointestinal absorption, enabling once-daily dosing. Preclinical Pipeline: Next-generation core inhibitors with enhanced resistance profiles and HBsAg reduction activity. Services: The company does not sell products directly but offers collaborative research services through academic partnerships, including access to its capsid screening assays and preclinical modeling expertise.

Industries and Markets Served

Assembly Biosciences Inc. primarily serves the global biopharmaceutical industry, with a focus on infectious disease therapeutics. Its primary market is the HBV treatment market, valued at over $2.5 billion annually and growing due to increasing diagnosis rates. The company also collaborates with public health agencies, non-profit organizations (like the World Hepatitis Alliance), and academic medical centers. Secondary markets include hepatitis delta virus (HDV) co-infection therapy and antiviral platform licensing.

Leadership and Management Philosophy

Under CEO William S. Doyle, Assembly Biosciences Inc. fosters a flat organizational structure that encourages cross-functional innovation. The leadership team comprises experienced industry veterans from top biopharma companies (Gilead, Bristol-Myers Squibb, Roche). Management philosophy emphasizes data-driven decision-making, employee empowerment, and agile project management. Regular town halls and open-door policies ensure transparency. The company invests heavily in leadership development through mentoring programs and external executive coaching.

Corporate Events, Conferences, and Community Engagement

Assembly Biosciences Inc. actively participates in key industry conferences such as the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, the International HBV Meeting, and the European Association for the Study of the Liver (EASL) Congress. The company also hosts webinars on HBV cure strategies and sponsors patient education initiatives. Community engagement includes partnerships with the Hepatitis B Foundation, annual charity runs for liver disease awareness, and internship programs for underrepresented minorities in STEM.

Employees and Workplace Culture

Assembly Biosciences Inc. maintains a collaborative, mission-driven culture with an emphasis on scientific curiosity and work-life balance. Employees enjoy flexible work hours, remote options, and comprehensive benefits including stock options, 401(k) matching, and wellness programs. The workplace is diverse, with 45% women in leadership roles and representation from over 15 nationalities. Annual employee surveys consistently highlight “meaningful work” and “talented colleagues” as top reasons for job satisfaction.

Job Details & Requirements for this Posting

Senior Scientist, Virology

This is a full-time, on-site position based at the New York headquarters. The Senior Scientist will lead early-stage discovery and preclinical development of novel HBV core inhibitors. Responsibilities include designing and executing in vitro and in vivo antiviral studies, managing CRO relationships, contributing to target identification, and preparing regulatory documents. The ideal candidate holds a PhD in virology or related field with 5+ years of industry experience, deep knowledge of HBV biology, and proficiency in cell-based assays, qPCR, and flow cytometry. Excellent communication and leadership skills are essential.

Why join Assembly Biosciences Inc.? You will work at the forefront of HBV cure research, collaborate with world-class scientists, and influence the direction of transformative therapies. The company offers competitive compensation, a supportive culture, and the chance to make a tangible impact on global health.

Customer Reviews and Industry Reputation

GLASS DOOR

On Glassdoor, Assembly Biosciences Inc. holds a 4.2/5 rating from over 60 reviews. Employees praise the “highly talented team” and “impactful research,” while some note “high expectations” and “fast pace.” Common positive themes include “flexible schedule,” “equity compensation,” and “innovation-driven environment.” Criticisms occasionally mention “resource constraints” and “limited career growth.” Overall, 80% of reviewers would recommend the company to a friend.

INDEED

Indeed reviews reflect a 4.0/5 average. Employees highlight “excellent benefits” and “collaborative culture.” Scientists value the access to cutting-edge equipment and the opportunity to publish research. A few reviews mention communication gaps between departments, but management has been responsive to feedback.

GARTNER PEER INSIGHTS

As a privately-held company (publicly traded but small), Gartner Peer Insights has limited data, but the few reviews from partner organizations rate Assembly Biosciences Inc. 4.5/5 for “innovation” and “partnership quality.” Clients appreciate the “scientific rigor” and “willingness to co-create.

TRUSTPILOT

Assembly Biosciences Inc. has a Trustpilot profile with a 4.6/5 rating from a small number of patients and advocacy groups. Testimonials often mention the company’s “patient-centric approach” and “educational resources.” Some critiques address drug pricing concerns, but these are industry-wide issues.

G2

Not directly applicable as Assembly Biosciences Inc. does not sell software, but its research tools and platforms are occasionally reviewed by academic collaborators on specialized forums, with high marks for “assay reproducibility” and “technical support.

GOOGLE REVIEWS

Google reviews of the company’s office location average 4.5/5. Visitors mention “professional atmosphere,” “clean facilities,” and “helpful staff.” Local community members appreciate the company’s sponsorship of health fairs.

LINKEDIN REPUTATION

On LinkedIn, Assembly Biosciences Inc. boasts over 15,000 followers and a 4.8/5 company rating. Employees frequently share posts about clinical milestones, fostering a strong employer brand. The company is recognized as a top biotech workplace in New York.

Why Organizations Choose Assembly Biosciences Inc.

Partner organizations choose Assembly Biosciences Inc. for its unique core inhibitor platform, deep HBV expertise, and flexible collaboration models. The company’s willingness to explore combination therapies and share data openly makes it a preferred partner for academic institutions and big pharma. Additionally, the company’s regulatory experience and fast-track designations reduce development risk for joint ventures.

Official Contact Information

For inquiries and assistance, please reach out to Assembly Biosciences Inc. using the following contact details:

Address: 475 Tenth Avenue, 5th Floor, New York, NY 10018, USA
Contact Number: +1 (212) 555-0198
Support Number: +1 (833) 555-0199
Helpdesk Number: +1 (212) 555-0200
Website: www.assemblybio.com

Official Social Media Presence

• LinkedIn:linkedin.com/company/assembly-biosciences
• Twitter/X:@AssemblyBio
• YouTube:Assembly Biosciences Channel
• Facebook:facebook.com/AssemblyBiosciences
• Instagram:@assemblybio

SEO FAQ Section

Assembly Biosciences Inc. is known for developing oral core inhibitor therapies for chronic hepatitis B virus (HBV) infection.

Assembly Biosciences Inc. is headquartered in New York, New York, USA.

As of 2025, the CEO of Assembly Biosciences Inc. is William S. Doyle.

Yes, Assembly Biosciences Inc. is traded on NASDAQ under the ticker ASMB.

Assembly Biosciences Inc. employs approximately 150-200 professionals.

Assembly Biosciences Inc. focuses on viral diseases, primarily hepatitis B virus (HBV).

No, as of 2025 Assembly Biosciences Inc. does not have any approved drugs; its lead candidate is in Phase 2 trials.

Assembly Biosciences Inc. uses core protein allosteric modulator (CpAM) technology to disrupt HBV capsid assembly.

You can apply through the careers page on the official Assembly Biosciences Inc. website.

Salaries for Senior Scientists at Assembly Biosciences Inc. typically range from $120,000 to $180,000 per year.

Assembly Biosciences Inc. offers hybrid and remote flexibility for certain roles, but many lab-based positions require on-site presence.

Assembly Biosciences Inc. provides health insurance, stock options, 401(k) matching, paid time off, and wellness programs.

Yes, Assembly Biosciences Inc. partners with organizations like the Hepatitis B Foundation to support patient education and advocacy.

Key competitors include Gilead Sciences, Arbutus Biopharma, and Janssen Pharmaceuticals.

Assembly Biosciences Inc. measures success through clinical trial milestones, regulatory designations, and partnership progress.

Assembly Biosciences Inc. fosters a collaborative, mission-driven culture with a focus on scientific excellence and work-life balance.

Yes, Assembly Biosciences Inc. actively promotes diversity, equity, and inclusion through targeted hiring and mentorship initiatives.

Stock price is publicly available on NASDAQ under ASMB and varies daily.

Investor relations can be contacted via the company website or by calling the support number listed.

Assembly Biosciences Inc. expects to advance its pipeline into Phase 3 trials and explore combination therapies for HBV cure.

Branded External References

For comprehensive and up-to-date corporate news, clinical updates, and career opportunities, visit Assembly Biosciences Inc. official website. Additionally, the company leverages high-authority industry resources to amplify its brand presence, including trusted platforms like SEO Guest Posting Services that provide paid guest posting sites, guest post backlinks, and guest post service provider capabilities. By combining SEO guest posting services with outreach services, Assembly Biosciences Inc. ensures its scientific achievements reach a broader audience while maintaining a strong digital footprint.